Dr. Nathan Haroun Tehrani, MD

Dr. Tehrani practices at NewYork-Presbyterian Queens in Flushing, New York, part of NewYork-Presbyterian Hospital.

Dr. Tehrani's NPI, 1295122018, was assigned on April 20, 2015. Dr. Tehrani graduated from American University of the Caribbean School of Medicine in 2015. Dr. Tehrani's New York license number on file is 296734.

Dr. Tehrani's primary practice is NewYork-Presbyterian Queens, at 56-45 Main Street, Flushing, NY 11355 in Queens County. The practice phone is (718) 670-2000.

Dr. Tehrani's primary practice is NewYork-Presbyterian Queens in Flushing, New York, part of NewYork-Presbyterian Hospital. The medical group on file is NewYork-Presbyterian Medical Group Queens. Dmand AI also links Dr. Tehrani to 2 more group practices and clinics, 1 dialysis center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Tehrani practices, 4 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Tehrani's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Tehrani is board certified in cardiovascular disease by the American Board of Internal Medicine. Dr. Tehrani has a license on file in New York.

Dmand AI lists aneurysm, atrial fibrillation and flutter, cardiomyopathy, chronic hypertension, chronic skin ulcer, coronary artery disease, heart failure and heart valve disorders among the conditions Dr. Tehrani treats.

CMS data shows 1,132 Medicare services from Dr. Tehrani across 16 procedure codes in 2024, for 528 Medicare patients. Medicare paid $65,269 for them.

CMS counts 528 Medicare patients who saw Dr. Tehrani in 2024. The largest group is 75 to 84, with 187 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 45% are also on Medicaid. Their average risk score is 2.34, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Tehrani's median patient age at 70, with 53% women.

In 2024, Dr. Tehrani wrote 1,142 Medicare Part D claims for 163 patients. 73% of them were for generic drugs. CMS names the drug for 997 of them, across 23 drugs with 11 or more claims each, at $250,745 in total drug cost. In 2023, CMS named 677 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Tehrani for performance year 2024, reported through an alternative payment model (APM). Dr. Tehrani accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 5 papers to Dr. Tehrani in 2019. 2019 was the busiest year, with 2. The most frequent topics are Hemodynamics, Predictive Value of Tests and Cardiac Catheterization. Dr. Tehrani's most frequent co-authors are Javid Alakbarli, MD, Richard B. Devereux, MD and Mark B. Ratcliffe, MD.

CMS Open Payments shows 38 general payments to Dr. Tehrani from 12 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 79% of the total. Abbott Laboratories paid the most, $872.

Dr. Tehrani graduated from American University of the Caribbean School of Medicine in 2015.

Dr. Tehrani is in network with 10 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.